

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SinoMab BioScience Limited

中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (“**Director(s)**”) of SinoMab BioScience Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Shanchun WANG (“**Mr. Wang**”) has been appointed as an executive Director of the Company with effect from 7 February 2024.

Mr. Shanchun WANG, aged 56, has been serving as the President (China) of the Company since the fourth quarter of 2022, and is mainly responsible for overseeing and managing the overall operation, as well as clinical development, of the Group in China. Mr. Wang also acts as a director and the legal representative of each of MediNexus Pharma (Shanghai) Limited* (興聯藥業(上海)有限公司) and SinoMab Biopharmaceutical (Nanjing) Limited (中抗生物製藥(南京)有限公司), and the legal representative of MediNexus Pharma (Suzhou) Limited and MediNexus Pharma (Beijing) Limited* (杏聯藥業(北京)有限公司), all are subsidiaries of the Company.

Mr. Wang has over 33 years extensive experience in the pharmaceutical industry. Prior to joining our Group, Mr. Wang served as the executive director of Sino Biopharmaceutical Limited (shares of which are listed on the Stock Exchange of Hong Kong Limited (stock code: 1177) during April 2015 to November 2022, and the president of Chia Tai-Tianqiang Pharmaceutical Holdings Co. Ltd. (“**CT Tianqing**”, a principal subsidiary of Sino Biopharmaceutical Limited) during January 2015 to January 2022. During Mr. Wang’s tenure in CT Tianqing from January 1997 to January 2022, he took up positions of deputy chief engineer, chief engineer, vice president, executive vice president and president. He has rich experience and practical achievements in corporate strategic management, organizational management, innovation research and development and product commercialization. Mr. Wang has been given various awards such as National Model Worker, Technology Advanced Worker of Jiangsu Province, Model Labour of Jiangsu Province, Shanghai Technology Advancement First Honour, Outstanding Entrepreneur of Jiangsu Province, Young and Middle-aged Expert with Outstanding Contribution of Jiangsu Province, Jiangsu Advanced Individual with Outstanding Contribution in Manufacture, and

* For identification purposes only

National Distinguished Leader in Pharmaceutical Quality Management, granted with the special allowances by the State Council, and elected as a representative of the 13th People's Congress of Jiangsu Province.

Mr. Wang graduated from Nanjing University of Chemistry in 1990 and studied pharmaceutical engineering at Tianjin University from 1999 to 2022 and obtained a Master's Degree.

As at the date of this announcement, Mr. Wang is interested in (i) 15,340,000 ordinary shares of the Company and (ii) 20,124,800 share options pursuant to 2022 share option scheme of the Company as his interest in the securities of the Company and its associated corporation within the meaning of Part XV of the Securities of Futures Ordinance (“SFO”) (Chapter 571 of the Laws of Hong Kong).

The Company will enter a letter of appointment with Mr. Wang. The initial length of services will commence from the date of appointment for a term of three years, subject to re-election and retirement as required by the second amended and restated articles of association of the Company (the “Articles”). Mr. Wang will hold office until the first annual general meeting of the Company at which he will be subject to re-election in accordance with the Articles. No remuneration and/or director's fee will be paid to Mr. Wang in respect of his appointment as an executive Director. The remuneration currently payable to Mr. Wang in respect of his employment as the President (PRC) of the Company is HK\$5,000,005 per annum, which was determined by reference to industry norm and market conditions and based on the services rendered to the Group, and, in addition, performance based discretionary bonus and shall be eligible to share incentive subject to internal approval. Mr. Wang has not and will not be entitled to receive additional remuneration for serving as other roles in the Group.

Saved as disclosed above, as at the date of this announcement, Mr. Wang (i) is not interested or is not deemed to have any other interests or short positions in the shares or underlying shares of the Company within the meaning of Part XV of the SFO (Chapter 571 of the Laws of Hong Kong); (ii) is independent from and has no relationship with Directors, senior management, substantial shareholders or controlling shareholders of the Company; (iii) has not held any other major appointments or qualifications or positions with the Company or other members of the Group; and (iv) has not held any other listed public companies in the past three years.

There is no information which is discloseable nor is Mr. Wang involved in any of the matters required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to express warmest welcome to Mr. Wang in joining the Board.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 7 February 2024

As at the date of this announcement, the executive directors are Dr. Shui On LEUNG and Mr. Shanchun WANG, the non- executive directors are Dr. Haigang CHEN, Mr. Xun DONG, Dr. Wenyi LIU, Dr. Jianmin ZHANG, Mr. Lei SHI, and the independent non-executive directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.